Skip to main content

Table 1 Clinicopathological characteristics, intrinsic molecular subtypes of PAM50, and PAM50-based ROR of the 59 NST and paired metaplastic components from 27 patients with MpBC

From: Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma

Case

MpBC subtype

Histologic components

Dissectible components

PAM50 subtype

ROR

Age

TNM stage

Stage

ER/PR/HER2

SBR grade

BT5

SPC

SPS/NST

SPS/NST

BL/BL

75/62

73

T3N0M0

IIB

(−/ −/ −)

(III, III)

BT34

SPC

SPS/NST

SPS/NST

BL/BL

80/80

63

T2N0M0

IIA

(−/ −/− in SPS; 5%/ −/− in NST)

(III, III)

BT42

SPC

SPS/SQC/NST

SPS/NST

BL/BL

52/50

53

T2N0M0

IIA

(−/ −/ −)

(III, III)

BT46

SPC

SPS/NST

SPS/NST

BL/BL

55/62

39

T1N0M0

IA

(−/ −/ −)

(III, III)

BT61

SPC

SPS/NST

SPS/ NST

BL/HER2e

64/ 85

69

T2N0M0

IIA

(−/ −/− in SPS; −/ −/ + in NST)

(III, III)

BT65

SPC

SPS/NST

SPS/NST

BL/BL

72/ 56

46

T1N0M0

IA

(−/ −/ −)

(III, III)

BT91

SPC

SPS/SQC/NST

SPS/NST

BL/BL

74/62

91

T4N1M0

IIIB

(−/ −/− in SPS; 20%/ −/− in NST)

(III, III)

BT95

MMC

SPS/MAT/NST

SPS/MAT/NST

BL/BL/BL

76/68/63

46

T3N1M0

IIIA

(−/ −/ −)

(III, II, III)

BT15

MMC

SPS/ RHA/ MAT/ NST

SPS/RHA/NST

BL/BL/BL

62/70/60

47

T3N0M0

IIB

(−/ −/ −)

(III, III, III)

BT118

MMC

SPS/OGS/MAT/ NST

SPS/OGS/MAT/NST

BL/BL/BL/BL

77/67/49/62

74

T2N0M0

IIA

(−/ −/ −)

(III, III, III, III)

BT122

SPC

SPS/NST

SPS/NST

BL/BL

70/59

54

T3N1M0

IIIA

(−/ −/ −)

(III, III)

BT127

SPC

SPS/SQC/NST

SPS/SQC/NST

BL/BL/ BL

86/56/71

60

T2N1M0

IIB

(−/ −/ −)

(III, III, III)

BT3

SCC

SQC/NST

SQC/NST

BL/LA

51/51

72

T4N3M0

IIIC

(−/ −/− in SCC; 70%/ −/− in NST)

(III, II)

BT83

SCC

SQC/NST

SQC/NST

BL/HER2e

56/70

48

T4N3M0

IIIC

(−/ −/− in SCC; 60%/ −/ −* in NST)

(III, II)

BT131

SCC

SQC/NST

SQC/ NST

BL/HER2e

56/90

49

T2N0M0

IIA

−/ −/− in SCC; −/ −/ + in NST

(III, III)

BT23

MHM

RHA/NST

RHA/NST

BL/BL

87/59

51

T3N0M0

IIB

−/ −/ −

(III, III)

BT57

MHM

RHA/NST

RHA/NST

BL/BL

62/54

72

T2N1M0

IIB

−/ −/ −

(III, III)

BT69

MHM

RHA/NST

RHA/NST

BL/HER2e

76/68

81

T3N1M0

IIIA

−/ −/− in RHA; −/ −/ + in NST

(III, III)

BT137

MHM

RHA/NST

RHA/NST

BL/LA

79/39

48

T1N0M0

IA

−/ −/− in RHA; 10%/ 5%/− in NST

(III, III)

BT79

MHM

RHA/SQC/NST

RHA/NST

BL/BL

79/67

44

T3N1M0

IIIA

−/ −/ −

(III, III)

BT6

MHM

MAT/NST

MAT/NST

BL/BL

58/77

43

T3N2M0

IIIB

−/ −/ −

(II, III)

BT44

MHM

MAT/SQC/NST

MAT/NST

BL/BL

45/62

56

T3N0M0

IIB

−/ −/ −

(II, II)

BT64

MHM

MAT/NST

MAT/NST

BL/BL

50/58

60

T2N0M0

IIA

−/ −/ −

(III, III)

BT71

MHM

MAT/NST

MAT/NST

BL/BL

50/57

54

T2N0M0

IIA

−/ −/ −

(III, III)

BT85

MHM

MAT/NST

MAT/NST

BL/BL

44/65

72

T1N0M0

IA

−/ −/ −

(II, III)

BT100

MHM

MAT/NST

MAT/NST

BL/BL

69/75

40

T3N1M0

IIIA

−/ −/ −

(III, III)

BT130

MHM

MAT/NST

MAT/NST

BL/BL

59/33

43

T3N1M0

IIIA

−/ −/ −

(II, III)

  1. *IHC2+, HER2 FISH−
  2. BL basal-like, HER2e HER2-enriched, LA luminal A, MHM metaplastic carcinoma with heterologous mesenchymal differentiation, MMC mixed metaplastic carcinoma, ROR risk of recurrence, SBR Scarff-Bloom-Richardson, SCC squamous cell carcinoma, SPC spindle cell carcinoma